ANALYSIS OF DRUG INTERACTIONS BETWEEN ORAL ANTINEOPLASTIC AGENTS AND CONCURRENT MEDICATIONS (submitted in 2019)
5PSQ-047
RIBOCICLIB SAFETY IN METASTATIC BREAST CANCER (submitted in 2019)
5PSQ-046
PREVALENCE OF NIVOLUMAB ADVERSE EVENTS IN ROUTINE CLINICAL PRACTICE (submitted in 2019)
5PSQ-045
OLARATUMAB: WHAT IS THE ECONOMIC IMPACT ON THE NATIONAL HEALTH SYSTEM? (submitted in 2019)
5PSQ-044
IMPACT OF DRUG INTERACTIONS IN HIGH DOSE METHOTREXATE ELIMINATION (submitted in 2019)
5PSQ-043
IMPLEMENTATION OF A PREPARATION PROTOCOL FOR CHEMOTHERAPY ADMIXTURES OF HIGH ECONOMIC IMPACT (submitted in 2019)
5PSQ-042
EVALUATION OF AN INFORMATION CHECKLIST FOR VALIDATION OF ANTINEOPLASTIC PRESCRIPTIONS (submitted in 2019)
5PSQ-041
CONSUMPTION OF HERBAL MEDICINE IN PATIENTS ON ORAL ANTICANCER DRUGS: STILL A LONG WAY TO GO! (submitted in 2019)
5PSQ-040
SECURITY PROFILE OF IBRUTINIB AS MONOTHERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA: EXPERIENCE IN A TERTIARY HOSPITAL (submitted in 2019)
5PSQ-039
PANCREATITIS INDUCED BY IMMUNOTHERAPY? TWO CASE REPORTS (submitted in 2019)
5PSQ-038
SAFETY OF CYCLIN DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF BREAST CANCER WITH POSITIVE HORMONAL RECEPTORS AND NEGATIVE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2. (submitted in 2019)
5PSQ-037
DOCETAXEL INDUCED NEUTROPENIC ENTEROCOLITIS: A CASE REPORT (submitted in 2019)
5PSQ-036
STOPP/START CRITERIA IN PATIENTS WITH HIV (submitted in 2019)
5PSQ-035
DUAL THERAPY WITH DOLUTEGRAVIR AND LAMIVUDINE: EFFICACY AND SAFETY. (submitted in 2019)
5PSQ-034
EVALUATION OF OSELTAMIVIR USE IN CLINICAL PRACTICE IN A SECOND LEVEL HOSPITAL. (submitted in 2019)
